COMMUNICABLE DISEASE 
CONTROL BRANCH
- Attention all doctors - 
Date: 27/02/2017     Contact telephone number: 1300 232 272  (24 hours/7 days)

 

ZOSTAVAX® VACCINE ADMINISTRATION ALERT

  • Use of shingles vaccine (Zostavax®) when contraindicated has resulted in a death in Australia.
  • DO NOT administer Zostavax® to patients with severe immunocompromise.

Take a detailed medical and medication history prior to vaccination.
Conditions that would contraindicate zoster vaccination include:

  • Anaphylaxis following a previous dose of any VZV-containing vaccine (either zoster or varicella vaccine), or anaphylaxis following any vaccine component (including gelatin or neomycin).
  • Pregnancy
  • Primary or acquired immunodeficiency
    • Current haematologic neoplasms: leukaemias, lymphomas, myelodysplastic syndromes
    • Post-transplant: solid organ (on immunosuppressive therapy)
    • Haematopoietic stem cell transplant (within 24 months)
    • Immunocompromised due to primary immunodeficiency
    • Symptomatic HIV or HIV with CD4 count of ≤200 per μL
    • Other significantly immunocompromising conditions
  • Immunosuppressive therapy (current or recent)
    • Chemotherapy or radiotherapy. Wait at least 6 months after the end of treatment and patients are demonstrated to be in remission.
    • Corticosteroids (short-term high dose, long-term lower dose). See table below:
    • All biologics and most disease-modifying anti-rheumatic drugs (DMARDs). See table below.

(This is not a complete list of all immunosuppressive medications. If on more than one agent or if any doubt do not administer Zostavax® and seek specialist advice about its use.)

Drug Group Some examples Comments re Zostavax® use
Anti-TNF  Etanercept, Infliximab, Adalimumab Contraindicated.
Zostavax can be used 1 month prior to treatment initiation or 12 months post treatment cessation.
IL-1 inhibition Anakinra
Costimulation
blockade
Abatacept
B-cell depletion
/inhibition
Rituximab
Immunomodulators
(antimetabolites)
Azathioprine, Methotrexate, 6-Mercaptopurine Contraindicated if >3.0mg/kg/day azathioprine, or >0.4mg/kg/week methotrexate, or >1.5mg/kg/day 6-mercaptopurine.
Zostavax can be used 1 month prior to treatment initiation or 3 months post treatment cessation.
Corticosteriod Prednisolone Complex – see The Australian Immunisation Handbook section 3.3.3.
T-cell activation
inhibition
Tacrolimus, Cyclosporine Contraindicated.
Zostavax can be used 1 month prior to treatment initiation or 3 months post treatment cessation
Others Cyclophosphamide,
Mycophenolate,
Sulfasalazine

Urgently seek specialist advice if Zostavax® is given to a person with severe immunocompromise.

For more information see http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home

Dr Ann Koehler - Director, Communicable Disease Control Branch
For all enquiries please contact the CDCB on 1300 232 272 (24 hours / 7 days)
Public – I3-A2

Download the official health alert here (PDF)
 

CONTACT US

Beckwith Park, 30 Tanunda Road Nuriootpa SA 5355
PO Box 868 Nuriootpa SA 5355
T 08 8565 8900 F 08 8311 1723
E This email address is being protected from spambots. You need JavaScript enabled to view it.

@countrysaphn

HEALTH PROFESSIONALS

THINGS WE DO

 

While the Australian Government Department of Health has contributed to the funding of this website, the information on this website does not necessarily reflect the views of the Australian Government and is not advice that is provided, or information that is endorsed, by the Australian Government. The Australian Government is not responsible in negligence or otherwise for any injury, loss or damage however arising from the use of or reliance on the information provided on this website.

© 2015 COUNTRY SA PHN  
Country SA PHN gratefully acknowledge the financial and other support from the Australian Government Department of Health